Gilbert Ko

POSTER: MM-548: Navigating Bispecifics Outpatient Step-Up Dosing: A Roadmap to Help Improve Safety and Access in the Real-World (NORTHSTAR)

Muhamed Baljević, Donald C. Moore, Hans C. Lee, Stephen Divers et autres

us (code pays fourni par la source)

MM-548: Navigating Bispecifics Outpatient Step-Up Dosing: A Roadmap to Help Improve Safety and Access in the Real-World (NORTHSTAR)

Muhamed Baljević, Donald C. Moore, Hans C Lee, Stephen Divers et autres

us (code pays fourni par la source)

Incidence and Recurrence of Ischemic Stroke in a Large Midwestern Healthcare System (P8-5.016)

N J Glowacki, Joseph Chase, Emily Durden, Gilbert Ko et autres

us (code pays fourni par la source)

EE215 INCIDENCE AND COSTS OF SECONDARY STROKE EVENTS IN PATIENTS WITH ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK OF NON-CARDIOEMBOLIC ORIGIN

Michael Head, Valerie Haley, Emily Durden, Steven Caproni et autres

us (code pays fourni par la source)

Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study

Binod Dhakal, Moshe Levy, Gilbert Ko, Jinghua He et autres

INTRODUCTION: Teclistamab is an established standard of care for the treatment of relapsed/refractory multiple myeloma (RRMM) based on MajesTEC-1 study results. United States (US)-based real-world studies of teclistamab treatment have had limited follow-up, were conducted in academic settings and/or had small sample …

us (code pays fourni par la source)

Abstract TP188: Real-World Assessment of Healthcare Resource Utilization and Expenditures Following Initial Ischemic Stroke or Transient Ischemic Attack of Non-Cardioembolic Origin

Michael Head, Valerie Haley, Steven Caproni, Emily Durden et autres

Introduction: Following an initial stroke, patients experience a high burden, including more than just inpatient or post-acute-care stays. This study evaluated the real-world clinical and economic burden experienced by patients following a primary IS or TIA of non-cardioembolic origin, stratified by the …

us (code pays fourni par la source)

Outcomes of Teclistamab (Tec) Step-Up Dosing in Outpatient/Hybrid Settings Among a Large Sample of Relapsed Refractory Multiple Myeloma (RRMM) Patients Treated with Tec

Binod Dhakal, Gilbert Ko, Jinghua He, Wenze Tang et autres

Real-world Outcomes Among Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Initiating Teclistamab (Tec) at a Large Community Oncology Center in the US

Yair Levy, Laura Ensley, Siraje Mahmud, Monica Lisi et autres

Real-World Long-Term Effectiveness and Safety Outcomes Among Patients Receiving Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Carlyn Tan, Tala Shekarkhand, David Nemirovsky, Andriy Derkach et autres

Real-World Safety Outcomes and Healthcare Resource Utilization (HCRU) During Outpatient, Inpatient, and Hybrid Step-up Dosing (SUD) of Teclistamab (Tec) and Talquetamab (Tal): A Chart Review Study

Cindy Varga, Jack Khouri, David Oveisi, Baylee Bryan et autres

Abstract TP273: Characteristics and Incidence of Stroke and Bleeding in Patients with a First-Ever Transient Ischemic Attack: A US Multi-Database Observational Study

Khaled Abdelgawwad, Carina Dinkel-Keuthage, Fernando Dursi, Elif İnan‐Eroğlu et autres

Introduction: Patients suffering from transient ischemic attack (TIA) are at high risk of ischemic stroke (IS). This study describes clinical characteristics and outcomes in patients with a first non-cardioembolic TIA. Methods: Using two US administrative claims databases (MarketScan and Optum’s de-identified Clinformatics® …

de, fi, us, ca (code pays fourni par la source)

Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review

Andrea Ferreira‐Gonzalez, Gilbert Ko, Nicole Fusco, Fiona Stewart et autres

Aim: Next-generation sequencing (NGS) of solid tumors can inform treatment decisions; however, uptake remains low. This objective of this systematic review was to identify barriers to and facilitators of NGS in US oncology settings.Materials & methods: Embase and MEDLINE were searched in …

us (code pays fourni par la source)